Biosimilars Europe 2016
Holiday Inn Kensington ForumLondon, UK Visit the Venue to read more
SMi Group’s 7th annual Biosimilars Europe conference returns to London this September!
The development of the Biosimilars market is growing exponentially with the industry forecast to be worth $25 billion by 2020. With the regulatory landscape evolving rapidly, it is important to understand the developments in the biosimilar guideline framework and the cohesion in legislation between Europe and the US.
With Europe leading the way in the field of Biosimilar development, it is important to get to grips with all areas in the product lifecycle from early stage developments, protein characterisation and analytical comparability to patent litigation, market access, pricing and reimbursement through to emerging markets and global developments. Every angle should be considered and taken account for through the development process and with the EU the most advanced market for biosimilars, accounting for 80% of global spending on these molecules, the learning curve for biosimilars is essentially still building and there are hurdles to overcome.
Group registrations not allowed
Accompanying persons not allowed
We don’t accept Online Abstracts
Holiday Inn Kensington Forum
97 Cromwell Rd,
+44 (0)20 7827 6000